Landscape Capital Management L.L.C. Makes New Investment in Bausch + Lomb Corporation $BLCO

Key Points

• Landscape Capital Management L.L.C. has purchased 100,000 shares of Bausch + Lomb Corporation, valued at approximately $1.45 million, during the first quarter of the year.
• Multiple hedge funds have increased their positions in Bausch + Lomb, with notable investments including Deutsche Bank AG investing $50.75 million.
• Analyst ratings on Bausch + Lomb show mixed reviews, with an average rating of "Hold" and a consensus price target of approximately $15.56.

Landscape Capital Management L.L.C. bought a new stake in shares of Bausch + Lomb Corporation (NYSE:BLCO - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 100,000 shares of the company's stock, valued at approximately $1,450,000.

Several other hedge funds have also recently modified their holdings of BLCO. Allianz Asset Management GmbH purchased a new position in Bausch + Lomb during the first quarter valued at approximately $4,712,000. Renaissance Technologies LLC bought a new position in Bausch + Lomb in the fourth quarter worth approximately $372,000. Tabor Asset Management LP bought a new position in Bausch + Lomb in the first quarter worth approximately $338,000. Dimensional Fund Advisors LP raised its stake in Bausch + Lomb by 66.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 109,619 shares of the company's stock worth $1,979,000 after buying an additional 43,740 shares in the last quarter. Finally, Millennium Management LLC bought a new position in Bausch + Lomb in the fourth quarter worth approximately $735,000. Hedge funds and other institutional investors own 11.07% of the company's stock.

Bausch + Lomb Stock Up 1.4%

Shares of BLCO traded up $0.20 during mid-day trading on Tuesday, hitting $14.83. 440,078 shares of the company traded hands, compared to its average volume of 778,855. Bausch + Lomb Corporation has a 1-year low of $10.45 and a 1-year high of $21.69. The company has a quick ratio of 0.98, a current ratio of 1.55 and a debt-to-equity ratio of 0.76. The company has a market capitalization of $5.25 billion, a PE ratio of -19.01, a price-to-earnings-growth ratio of 1.49 and a beta of 0.63. The business has a 50 day moving average of $13.95 and a 200 day moving average of $13.47.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.01. Bausch + Lomb had a negative net margin of 5.58% and a positive return on equity of 2.33%. The company had revenue of $1.28 billion for the quarter, compared to the consensus estimate of $1.25 billion. During the same quarter in the prior year, the company earned $0.13 EPS. Bausch + Lomb's quarterly revenue was up 5.1% on a year-over-year basis. Bausch + Lomb has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Bausch + Lomb Corporation will post 0.74 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently commented on BLCO. Wells Fargo & Company boosted their price objective on shares of Bausch + Lomb from $12.00 to $15.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 31st. Citigroup boosted their target price on shares of Bausch + Lomb from $13.00 to $15.00 and gave the stock a "neutral" rating in a report on Wednesday, July 9th. Morgan Stanley boosted their target price on shares of Bausch + Lomb from $12.00 to $13.00 and gave the stock an "equal weight" rating in a report on Friday, August 1st. Zacks Research upgraded shares of Bausch + Lomb to a "hold" rating in a report on Tuesday, August 12th. Finally, HC Wainwright boosted their target price on shares of Bausch + Lomb from $15.00 to $16.00 and gave the stock a "buy" rating in a report on Thursday, July 31st. Three analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Bausch + Lomb currently has a consensus rating of "Hold" and a consensus target price of $15.56.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.